The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Stocks may have brushed up against record highs Monday. However, a looming threat is just a couple weeks away once profit reports from the second quarter hit.
Analysts have been taking a dimmer view of what is ahead for earnings. They've already forecast a decline for the first three quarters of 2019. Now companies are echoing those concerns with a level of pessimism not often seen from corporate America.
Ahead of a season that starts in earnest the week of July 15, 77% of the 113 companies that have issued earnings per share guidance have warned that their numbers will be worse than what Wall Street analysts are estimating, according to FactSet.
That total of 87 companies is well above the typical level of 70% negative pre-announcements and the second-worst level since FactSet started keeping track in 2006. The worst was in the first quarter of 2016, which saw 92 negative such warnings.
At a time when the Dow Jones Industrial Average of blue chip stocks is coming off its best June since 1938, a wobbly profit picture doesn't do much to instill confidence that such an aggressive rally can continue. Earnings for the S&P 500, which had its best June since 1955, are projected to decline 2.6% from the same period a year ago.
"The harsh reality is data is going to impact sentiment," said Michael Yoshikami, founder of Destination Wealth Management. "I don't think it's something that can be ignored. Even though markets are at all-time highs, the economy is definitely slowing."
The issues with earnings now are multi-pronged but tied mostly to tariffs and waning global growth.
In terms of sectors, the two with the biggest negative pre-announcements — information technology and health care — are at the center of the tariff battle between the U.S. and its global trading partners, particularly China.
At the industry level, semiconductors and equipment along with health-care equipment and supplies and life sciences tools and services have seen the highest number of negative pre-announcements.
Technology has been at the core of President Donald Trump's tariffs against $250 billion worth of Chinese goods. At the same time, his steel and aluminum duties are making a direct hit on the health-care industry, impacting about $1.8 billion worth of medical imports, according to Tara O'Neill Hayes, the deputy director of health-care policy for the American Action Forum.
The total tariff impact will cost the industry about $400 million, Hayes wrote in a recent report. In addition to tariffs, health care also faces a serious regulatory risk ahead, with leaders in both parties expressing interest in curbing the amount pharmaceutical companies can charge for their drugs.
Multinationals, in general, also are seeing a big tariff impact. FactSet estimates that companies doing more than half their sales outside the U.S. are looking at a more than 9% earnings decline on a year-over-year basis.
Determining the market impact is difficult, but the downbeat sentiment from companies will give investors plenty to think about as Wall Street tries to build on a Dow gain this year of 14.4%.
"Stocks are priced for perfection. You haven't seen too much suffering yet, but it's kind of incipient. It's creeping into the numbers little by little," said Mitchell Goldberg, president of ClientFirst Strategy. "When stocks are priced for perfection, even little things become insurmountable."
One major attribute the market has going for it is that even at a slower pace, the U.S. is still outgrowing the rest of the world. However, mounting headwinds could send investors further into safe haven assets like bonds and gold, which have benefited during the intensifying U.S-China trade dispute.
"If you're worried about earnings, you should be taking some chips off the table," Goldberg said. "We've had a real nice rally this year. I wouldn't be surprised if we had a pullback."